全文获取类型
收费全文 | 447篇 |
免费 | 34篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 32篇 |
妇产科学 | 9篇 |
基础医学 | 73篇 |
口腔科学 | 11篇 |
临床医学 | 47篇 |
内科学 | 97篇 |
皮肤病学 | 23篇 |
神经病学 | 12篇 |
特种医学 | 43篇 |
外科学 | 30篇 |
综合类 | 35篇 |
预防医学 | 26篇 |
眼科学 | 3篇 |
药学 | 30篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 2篇 |
2021年 | 5篇 |
2020年 | 4篇 |
2019年 | 6篇 |
2018年 | 7篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 8篇 |
2014年 | 12篇 |
2013年 | 16篇 |
2012年 | 13篇 |
2011年 | 12篇 |
2010年 | 20篇 |
2009年 | 24篇 |
2008年 | 13篇 |
2007年 | 19篇 |
2006年 | 17篇 |
2005年 | 18篇 |
2004年 | 6篇 |
2003年 | 10篇 |
2002年 | 11篇 |
2001年 | 11篇 |
2000年 | 8篇 |
1999年 | 17篇 |
1998年 | 36篇 |
1997年 | 28篇 |
1996年 | 15篇 |
1995年 | 14篇 |
1994年 | 15篇 |
1993年 | 15篇 |
1992年 | 8篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 6篇 |
1986年 | 4篇 |
1985年 | 11篇 |
1984年 | 3篇 |
1983年 | 8篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1971年 | 3篇 |
1969年 | 1篇 |
1955年 | 1篇 |
排序方式: 共有499条查询结果,搜索用时 15 毫秒
81.
Kayexalate: a new cause of neonatal bowel opacification 总被引:1,自引:0,他引:1
82.
83.
Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain 总被引:3,自引:0,他引:3
84.
Complications of embolization: analysis of 410 procedures 总被引:1,自引:0,他引:1
85.
J Terencio de las Aguas 《Acta leprologica》1983,1(3):143-150
The importance of polichemotherapy in multibacilar leprosy (LL and LD) in patients without any previous therapy as in those diagnosticated and under monotherapy most of all in the resistance patients is presented. Sulphones, clofazimine and rifampicine are selected as first rate drugs and protionamide-etionamide as second rate drugs. The therapy plans with the association of two and three drugs and the convenience of continuing indefinitely with at least one of the drugs are presented insisting on the advantages of the clofazimine-sulphones and rifampicine-sulphones associations. The necessity of immunotherapy for recover of celular immunity against the bacilus, is the only form of preventing relapses and drug resistance. 相似文献
86.
87.
Since the 1980s, the occurrence of pertussis cases in developed countries has increased and shifted towards older age groups. This resurgence follows 30 years of intense mass vaccination, and has been attributed primarily to three factors: (1) more effective diagnosis of the disease, (2) waning of vaccine-induced immunity, and (3) loss of vaccine efficacy due to the emergence of new Bordetella pertussis strains. Here we develop and analyse a mathematical model to assess the plausibility of these hypotheses. We consider that exposure to B pertussis through natural infection or vaccination induces an immune response that prevents severe disease but does not fully prevent mild infections. We also assume that these protective effects are temporary due to waning of immunity. These assumptions, describing the mode of action of adaptive immunity, are combined with a standard transmission model. Two distinct epidemiological scenarios are detected: under low transmission, most infections lead to severe disease; under high transmission, mild infections are frequent, boosting clinical immunity and maintaining low levels of severe disease. The two behaviours are separated by a reinfection threshold in transmission. As a result, the highest incidence of severe disease is expected to occur at intermediate transmission intensities--near the reinfection threshold--suggesting that pertussis resurgence may be induced by a reduction in transmission, independently of vaccination. The model is extended to interpret the outcomes of current control measures and explore scenarios for future interventions. 相似文献
88.
89.
BackgroundRheumatoid arthritis is the most common chronic inflammatory disease in the UK. Serological status such as rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) positivity predict poor outcomes. Early intensive treatment regimens targeting remission reduce disease activity, structural damage, and long-term disability. However, we do not know whether all patients with active disease should have such intensive treatment regimens. Can serological status be used to predict the need for intensive therapy?MethodsWe analysed samples from a published randomised controlled trial which compared four treatment regimens in patients with early active rheumatoid arthritis (disease duration <2 years): methotrexate monotherapy, double therapy (methotrexate plus either ciclosporin or prednisolone), and triple therapy (methotrexate plus ciclosporin plus prednisolone). The trial randomised 467 patients (68% female, median age 54 years [IQR 46–63]). Disease activity was assessed with the disease activity score of 28 joints (DAS28). Remission was defined as DAS28 less than 2·6 at 24 months. RF isotypes (IgM and IgA) and ACPA levels were measured with commercial ELISA kits. Statistical analysis used Pearson's chi-squared test.Findings402 (86%) patients were positive for IgM RF, 346 (74%) for IgA RF, and 346 (74%) for ACPA. 98 (21%) patients achieved remission at 24 months. In RF IgM negative cases (n=65) the proportion of patients achieving remission at 24 months was similar in all treatment groups (25%, 22%, and 30% for monotherapy, double therapy, and triple therapy, respectively). In RF IgM positive cases, significantly fewer patients achieved remission with monotherapy (13/65, 17%) and double therapy (24/157, 15%) than with triple therapy (27/80, 34%) (p=0·001). There were similar, consistent findings with IgA RF and ACPA, with significantly more seropositive patients achieving remission with triple therapy than with monotherapy.InterpretationContemporary treatment of rheumatoid arthritis emphasises the use of intensive therapy to achieve remission. However, we have shown that not all patients require such an aggressive approach to therapy. Given the heterogeneity of the diease, treatment should be personalised to the individual, which would minimise costs of treatment as well as potentially toxic side-effects. Our study shows that only seropositive patients with rheumatoid arthritis should be given more intensive therapies.FundingNational Institute for Health Research. 相似文献
90.
Ewout?P?Boesaard Ingrid?P?Vogelaar Peter?Bult Carla?AP?Wauters J?Han?JM?van Krieken Marjolijn?JL?Ligtenberg Rachel?S?van der Post Nicoline?HoogerbruggeEmail author 《Hereditary cancer in clinical practice》2014,12(1):21
MUTYH- associated polyposis (MAP) is an autosomal recessive disease, which predisposes to polyposis and colorectal cancer. There is a trend towards an increased risk of breast cancer in MAP patients, with a remarkable proportion of papillary breast cancers. To determine whether MUTYH mutations are associated with this specific and rare type of breast cancer, 53 unselected patients with papillary breast cancer were analyzed for founder mutations in the MUTYH gene. No germline mutations were identified, indicating that biallelic MUTYH mutations are not a frequent underlying cause for the development of papillary carcinomas of the breast. 相似文献